Taken together, these findings suggest that the FDA-approved D2R agonist cabergoline decreases SCLC progression by reducing tumour angiogenesis and hypoxia through apoptosis of tumour-associated endothelial cells, leading to decreased proliferation of cancer cells within the SCLC PDX. Here, DRD2 is linked to neoplasm.